{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:27:01Z","timestamp":1785306421924,"version":"3.55.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T00:00:00Z","timestamp":1538265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.bone.2018.09.020","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T14:29:21Z","timestamp":1538058561000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"special_numbering":"C","title":["Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"120","author":[{"given":"Adolfo","family":"D\u00edez-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik F.","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Kendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Krege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Delgado-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bone.2018.09.020_bb0005","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/jbmr.3067","article-title":"Effect of teriparatide or risedronate in elderly patients with a recent pertrochanteric hip fracture: final results of a 78-week randomized clinical trial","volume":"32","author":"Malouf-Sierra","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"19","key":"10.1016\/j.bone.2018.09.020_bb0010","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bone.2018.09.020_bb0015","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2018.09.020_bb0020","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bone.2014.07.014","article-title":"The effects of teriparatide therapy at the hip in patients with osteoporosis","volume":"67","author":"Eriksen","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.09.020_bb0025","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00198-015-3353-1","article-title":"Patients with prior vertebral or hip fractures treated with teriparatide in the direct assessment of nonvertebral fractures in community experience (DANCE) observational study","volume":"27","author":"Beall","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.09.020_bb0030","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00198-016-3888-9","article-title":"Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States","volume":"28","author":"Burge","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2018.09.020_bb0035","article-title":"Hip and other fracture risk in patients receiving teriparatide in real-world clinical practice: pooled data from four prospective observational studies","author":"Silverman","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.09.020_bb0040","first-page":"349","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"g7647","author":"Shamseer","year":"2015","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bone.2018.09.020_bb0045","author":"US Food and Drugs Administration"},{"key":"10.1016\/j.bone.2018.09.020_bb0050","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br. Med. J."},{"issue":"9","key":"10.1016\/j.bone.2018.09.020_bb0055","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat. Med."},{"issue":"7109","key":"10.1016\/j.bone.2018.09.020_bb0060","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.bone.2018.09.020_bb0065","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.bone.2018.09.020_bb0070","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2018.09.020_bb0075","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","article-title":"Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases","volume":"47","author":"Miyauchi","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.09.020_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2018.09.020_bb0085","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bone.2018.09.020_bb0090","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00774-008-0871-3","article-title":"Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study","volume":"26","author":"Miyauchi","year":"2008","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2018.09.020_bb0095","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.09.020_bb0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.bone.2018.09.020_bb0105","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2018.09.020_bb0110","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1185\/030079906X104768","article-title":"A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study","volume":"22","author":"Kung","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bone.2018.09.020_bb0115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-005-2002-5","article-title":"Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis","volume":"17","author":"Hwang","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.09.020_bb0120","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1742-1241.2008.01768.x","article-title":"Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial","volume":"62","author":"Anastasilakis","year":"2008","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.bone.2018.09.020_bb0125","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.090315","article-title":"Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"24","author":"Recker","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2018.09.020_bb0130","doi-asserted-by":"crossref","first-page":"CR442","DOI":"10.12659\/MSM.881905","article-title":"Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life","volume":"17","author":"Panico","year":"2011","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.bone.2018.09.020_bb0135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2018.09.020_bb0140","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/jbmr.1870","article-title":"Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial","volume":"28","author":"Gl\u00fcer","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"9886","key":"10.1016\/j.bone.2018.09.020_bb0145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2018.09.020_bb0150","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.bone.2018.09.020_bb0155","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2018.09.020_bb0160","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study","volume":"101","author":"Dempster","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.09.020_bb0165","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2018.09.020_bb0170","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/jbmr.2825","article-title":"Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the SHOTZ study","volume":"31","author":"Dempster","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2018.09.020_bb0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00198-006-0204-0","article-title":"Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk \u2013 a meta-analysis","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.09.020_bb0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2474-12-209","article-title":"The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women","volume":"12","author":"Hopkins","year":"2011","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.bone.2018.09.020_bb0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1742-1241.2011.02837.x","article-title":"Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials","volume":"66","author":"Han","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.bone.2018.09.020_bb0190","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.09.020_bb0195","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00198-017-4175-0","article-title":"Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis","volume":"28","author":"Saito","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2018.09.020_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016190","article-title":"Targeted regeneration of bone in the osteoporotic human femur","volume":"6","author":"Poole","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2018.09.020_bb0205","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1359\/jbmr.090820","article-title":"Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study","volume":"25","author":"Borggrefe","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2018.09.020_bb0210","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-016-3534-6","article-title":"Teriparatide for osteoporosis: importance of the full course","volume":"27","author":"Lindsay","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2018.09.020_bb0215","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bone.2018.09.020_bb0220","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2018.09.020_bb0225","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2018.09.020_bb0230","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/jbmr.2496","article-title":"Co-administration of antirsorptive and anabolic agents: a missed opportunity","volume":"30","author":"Seeman","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2018.09.020_bb0235","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bone.2016.02.009","article-title":"Concurrent administration of PTH and antiresorptives: additive effects or DXA cosmetics","volume":"86","author":"Eriksen","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.09.020_bb0240","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1001\/archinte.162.20.2297","article-title":"Parathyroid hormone for treatment of osteoporosis","volume":"162","author":"Crandall","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bone.2018.09.020_bb0245","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2018.09.020_bb0250","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2018.09.020_bb0255","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2018.09.020_bb0260","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2018.09.020_bb0265","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N. Engl. J. Med."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218303600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218303600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T14:38:19Z","timestamp":1565275099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328218303600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":53,"alternative-id":["S8756328218303600"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2018.09.020","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734167917.793584750","asserted-by":"object"}]},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2018.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}